Zanobini Marco, Manganiello Sabrina, Bonalumi Giorgia, Biondi Raoul, Russo Marco, Mapelli Massimo, Alamanni Francesco, Saccocci Matteo
Department of Cardiac Surgery, IRCCS - Centro Cardiologico Monzino, Università degli Studi di Milano, Via C. Parea 4, 20138, Milano, Italy.
Department of CardioVascular Surgery, Heart Center - University Hospital of Zurich, Zurich, Switzerland.
J Cardiothorac Surg. 2017 Dec 13;12(1):114. doi: 10.1186/s13019-017-0680-7.
Valve-in-Valve (VIV) Transcatheter Aortic Valve Replacement (TAVR) is now the treatment of choice in high-surgical-risk patients with failing aortic bioprosthesis. Although less performed, VIV-Transcatheter Mitral Valve Replacement (TMVR) is a valid treatment option for selected high-risk patients with degenerated mitral bioprostheses. Several cases of elective ViV- TAVR and -TMVR have been reported but only few were performed in critical hemodynamic conditions.
We report the case of a patient underwent balloon-expandable transapical mitral valve-in-valve implantation in an emergency setting due to a severe stenosis of a bioprosthesis in mitral position. The procedure was successfully performed, with no residual mitral regurgitation or paravalvular leaks, and uneventful.
Transcatheter transapical mitral valve-in-valve implantation could represent a feasible and effective strategy even in critical setting.
瓣中瓣经导管主动脉瓣置换术(VIV-TAVR)目前是主动脉生物瓣功能衰竭的高手术风险患者的首选治疗方法。虽然瓣中瓣经导管二尖瓣置换术(VIV-TMVR)开展较少,但对于选定的二尖瓣生物瓣退化的高风险患者而言,它是一种有效的治疗选择。已有多例择期VIV-TAVR和VIV-TMVR的病例报告,但只有少数是在严重血流动力学情况下进行的。
我们报告了一例患者,因其二尖瓣位生物瓣严重狭窄,在紧急情况下接受了球囊扩张经心尖二尖瓣瓣中瓣植入术。手术成功完成,无残余二尖瓣反流或瓣周漏,且过程顺利。
即使在危急情况下,经导管经心尖二尖瓣瓣中瓣植入术也可能是一种可行且有效的策略。